Abstract
We investigated the blood pressure (BP) lowering efficacy of two dual antihypertensive therapies, the amlodipine/benazepril and benazepril/hydrochlorothiazide combinations, according to sodium sensitivity risk (SSR) as assessed by ambulatory BP monitoring (ABPM). In a multi-center, randomized, actively-controlled, parallel-group trial, patients with a clinic systolic/diastolic BP of 140 to 179/90 to 109 mmHg while on benazepril 10 mg daily monotherapy, received 24-week antihypertensive treatment with amlodipine/benazepril 5/10 mg (n = 213) or benazepril/hydrochlorothiazide 10/12.5 mg (n = 212). SSR was assessed with two 24-h ABPM parameters, BP dipper status at night and 24-h mean heart rate. The amlodipine/benazepril combination, compared with benazepril/hydrochlorothiazide combination, showed greater BP lowering effect in 304 patients with low/intermediate SSR, but smaller BP lowering effect in 121 patients with high SSR, with significant (P ≤ 0.046) interaction for 24-h, daytime and morning systolic BP. Indeed, in comparison with the benazepril/hydrochlorothiazide group, 24-h and daytime systolic BP reductions in the amlodipine/benazepril group were 4.19 and 5.17 mmHg, respectively, greater in patients with low/intermediate SSR, while morning systolic BP reductions was 10.8 mmHg smaller in patients with high SSR. Similar trends were observed for the other systolic BP measurements and diastolic BP measurements, although statistical significance was not attained (P ≥ 0.069). Sensitivity analysis in 367 patients with sustained hypertension was confirmatory. In conclusion, the antihypertensive treatment effect of the amlodipine/benazepril and benazepril/hydrochlorothiazide combinations was dependent on SSR as assessed by ABPM, with the former combination being more efficacious in patients with low/intermediate SSR, but less efficacious in patients with high SSR.

This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout


Similar content being viewed by others
Data availability
Consent given by study participants did not include data sharing with third parties. Anonymized data can be made available to investigators for targeted research based on a motivated request to be addressed to the corresponding author via jiguangwang@rjh.com.cn.
References
Huang L, Trieu K, Yoshimura S, Neal B, Woodward M, Campbell NRC, et al. Effect of dose and duration of reduction in dietary sodium on blood pressure levels: systematic review and meta-analysis of randomised trials. BMJ. 2020;368:m315.
Suckling RJ, He FJ, Markandu ND, MacGregor GA. Modest salt reduction lowers blood pressure and albumin excretion in impaired glucose tolerance and type 2 diabetes mellitus: a randomized double-blind trial. Hypertension. 2016;67:1189–95.
Mancia G, Kreutz R, Brunstrom M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41:1874–2071.
Vogt L, Marques FZ, Fujita T, Hoorn EJ, Danser AHJ. Novel mechanisms of salt-sensitive hypertension. Kidney Int. 2023;104:690–7.
Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2019). Hypertens Res. 2019;42:1235–481.
Schulz M, Krueger K, Schuessel K, Friedland K, Laufs U, Mueller WE, et al. Medication adherence and persistence according to different antihypertensive drug classes: a retrospective cohort study of 255,500 patients. Int J Cardiol. 2016;220:668–76.
Santos EM, Cunha LCC, Dias RSC, Cruz Diniz MC, Brito DJA, Teixeira TCS, et al. Dietary evaluation of sodium intake in patients with chronic kidney disease. Nutr Hosp. 2023;40:96–101.
Huang QF, Cheng YB, Guo QH, Liu CY, Kang YY, Sheng CS, et al. Clinic and ambulatory blood pressure in relation to the interaction between plasma advanced glycation end products and sodium dietary intake and renal handling. Hypertens Res. 2022;45:665–74.
Kurzhagen JT, Titze S, Buschges-Seraphin B, Schiffer M, Schneider MP, Eckardt KU, et al. Spot urinary sodium in CKD patients: correlation with 24h-excretion and evaluation of commonly used prediction equations. BMC Nephrol. 2024;25:210.
Zhou E, Lei R, Tian X, Liu C, Guo J, Jin L, et al. Association between salt sensitivity of blood pressure and the risk of hypertension in a Chinese Tibetan population. J Clin Hypertens. 2023;25:453–62.
Weinberger MH. Salt sensitivity of blood pressure in humans. Hypertension. 1996;27:481–90.
Castiglioni P, Parati G, Brambilla L, Brambilla V, Gualerzi M, Di Rienzo M, et al. Detecting sodium-sensitivity in hypertensive patients: information from 24-hour ambulatory blood pressure monitoring. Hypertension. 2011;57:180–5.
Huang QF, Zhang D, Luo Y, Hu K, Wu Q, Qiu H, et al. Comparison of two single-pill dual combination antihypertensive therapies in Chinese patients: a randomized, controlled trial. BMC Med. 2024;22:28.
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.
Takahashi H, Saito K, Yakura N. Validation of Omron HEM-9200T, a home blood pressure monitoring device for the upper arm, according to the American National Standards Institute/Association for the Advancement of Medical Instrumentation/International Organization for Standardization 81060-2:2013 protocol. J Hum Hypertens. 2022;36:416–9.
Palatini P, Frigo G, Bertolo O, Roman E, Da Corta R, Winnicki M. Validation of the A&D TM-2430 device for ambulatory blood pressure monitoring and evaluation of performance according to subjects’ characteristics. Blood Press Monit. 1998;3:255–60.
Ojji DB, Mayosi B, Francis V, Badri M, Cornelius V, Smythe W, et al. Comparison of dual therapies for lowering blood pressure in black Africans. N Engl J Med. 2019;380:2429–39.
Jamerson KA, Bakris GL, Weber MA. 24-hour ambulatory blood pressure in the ACCOMPLISH trial. N Engl J Med. 2010;363:98.
Fulvio MD. Inflammatory pathways of sulfonamide diuretics: insights into SLC12A Cl(-) symporters and additional targets. Cell Physiol Biochem. 2025;59:1–24.
Agarwal R, Verma A, Georgianos PI. Diuretics in patients with chronic kidney disease. Nat Rev Nephrol. 2025;21:264–78.
Polina I, Domondon M, Fox R, Sudarikova AV, Troncoso M, Vasileva VY, et al. Differential effects of low-dose sacubitril and/or valsartan on renal disease in salt-sensitive hypertension. Am J Physiol Ren Physiol. 2020;319:F63–F75.
Yang C, Isaeva E, Shimada S, Kurth T, Stumpf M, Zheleznova NN, et al. Inhibition of mTORC2 promotes natriuresis in Dahl salt-sensitive rats via the decrease of NCC and ENaC activity. Am J Physiol Ren Physiol. 2024;327:F435–F49.
Fujiwara T, Tomitani N, Kanegae H, Kario K. Comparative effects of valsartan plus either cilnidipine or hydrochlorothiazide on home morning blood pressure surge evaluated by information and communication technology-based nocturnal home blood pressure monitoring. J Clin Hypertens. 2018;20:159–67.
Kondo K, Toh R, Ishida T, Mori K, Yasuda T, Hirata K. Comparison of telmisartan/amlodipine and telmisartan/hydrochlorothiazide in the treatment of Japanese patients with uncontrolled hypertension: the TAT-Kobe study. Blood Press Monit. 2016;21:171–7.
Tani S, Asayama K, Oiwa K, Harasawa S, Okubo K, Takahashi A, et al. The effects of increasing calcium channel blocker dose vs. adding a diuretic to treatment regimens for patients with uncontrolled hypertension. Hypertens Res. 2017;40:892–8.
Ushigome E, Matsumoto S, Oyabu C, Ushigome H, Yokota I, Hasegawa G, et al. Olmesartan with azelnidipine versus with trichlormethiazide on home blood pressure variability in patients with type II diabetes mellitus. J Am Soc Hypertens. 2017;11:140–7.
Kario K, Ishikawa J, Pickering TG, Hoshide S, Eguchi K, Morinari M, et al. Morning hypertension: the strongest independent risk factor for stroke in elderly hypertensive patients. Hypertens Res. 2006;29:581–7.
Asayama K, Ohkubo T, Kikuya M, Obara T, Metoki H, Inoue R, et al. Prediction of stroke by home “morning” versus “evening” blood pressure values: the Ohasama study. Hypertension. 2006;48:737–43.
Guo QH, Cheng YB, Zhang DY, Wang Y, Huang QF, Sheng CS, et al. Comparison between home and ambulatory morning blood pressure and morning hypertension in their reproducibility and associations with vascular injury. Hypertension. 2019;74:137–44.
Kario K, Wang JG, Chia YC, Wang TD, Li Y, Siddique S, et al. The HOPE Asia network 2022 up-date consensus statement on morning hypertension management. J Clin Hypertens. 2022;24:1112–20.
Liu J, Li Y, Asayama K, Zhang XJ, Cheng HM, Park S, et al. Asian expert consensus on nocturnal hypertension management. Hypertension. 2025;82:945–56.
Kario K, Hoshide S, Chia YC, Buranakitjaroen P, Siddique S, Shin J, et al. Guidance on ambulatory blood pressure monitoring: a statement from the HOPE Asia Network. J Clin Hypertens. 2021;23:411–21.
Acknowledgements
The authors gratefully acknowledge the voluntary participation of the patients and the contribution of the investigators from 20 hospitals and community health centers.
The ACEI/CCB Versus ACEI/DIU Combination Antihypertensive Therapy in Chinese Hypertensive Patients (ACvAD) investigators
Kai Zhao7, Yihong Luo8, Bing Deng9, Xin Chen10, Yinglong Qiu11, Mei-Ling Wang12, Zhihong Zhou13, Leijun Wang14, Jiahong Wang15, Ji-Guang Wang16, Yan Li16, Guibin He17, Hong Yu18, Ping Wang19, Yingmin Lu20, Yanping Zhang21, Yong Luo22, Jianhua Chen23, Min Liu24, Qing Peng25, and Jianqiang Xiao26
Funding
The study was partially funded by Di’ao Pharmaceuticals (Chengdu, Sichuan Province, China). The study investigators were also supported by the National Natural Science Foundation of China (grants 82370426, 82270469, 82070432, and 81970353), the Ministry of Science and Technology (2022YFC3601302 and 2024ZD0527304), Beijing, China, the Shanghai Municipal Health Commission (202340035 and 2024ZZ1028 and a Grant for Leading Academics 2022LJ022), and the Shanghai Talent Work Bureau (an Oriental Talent Program BJWS2024086).
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Conflict of interest
JGW reports having received lecture and consulting fees from Novartis, Omron, Servier, and Viatris. The other authors declare no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Huang, QF., Zhang, D., Luo, Y. et al. Antihypertensive treatment effect of two dual therapies according to sodium sensitivity. Hypertens Res 49, 340–349 (2026). https://doi.org/10.1038/s41440-025-02382-x
Received:
Revised:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41440-025-02382-x


